

Roche, Novartis, Sanofi Capital Protected, Express Certificate (HUF)

- Underlying: Shares of Novartis AG, Roche Holding AG and Sanofi Aventis S.A.
- Annual yield opportunity of 23.05%*
- 100% capital protection at the end of the term
- Term: 1 to 3 years (early redemption possible)
- Further information on opportunities/risks on the following pages

*Excluding transaction fees

Investment product with capital protection
Express Certificate



This certificate provides the opportunity for early redemption each year and enables investors to obtain a yield of 23.05% per year if the prices of Novartis, Roche and Sanofi shares quote on one of the annual valuation days at or above their starting value. If at least one of the shares quotes below the starting value, the term extends by another year – up to a maximum of 3 years.

Issuer¹	Raiffeisen Bank International AG
ISIN	AT0000A34600
Issue price	100%
Nominal value	HUF 10,000
Subscr. period²	May 3, 2023 - May 24, 2023
Initial valuation date	May 25, 2023
Issue value date	May 26, 2023
Annual valuation dates	
May 23, 2024; May 22, 2025; May 21, 2026	
Early maturity dates	
May 28, 2024; May 27, 2025; May 27, 2026	
Underlying	Novartis AG common share Roche Holding AG common share Sanofi Aventis S.A. common share
Calculation agent of underlying	
Novartis AG	Swiss Exchange
Roche Holding AG	Swiss Exchange
Sanofi Aventis S.A.	Euronext Paris
Starting value	Closing price of the underlying at the initial valuation date
Final value	Closing price of the underlying at the final valuation date
Termination levels	
1) 100%, 2) 100%, 3) 100% of the starting value	
Observation of the termination levels	
at each annual valuation date (closing prices)	
Termination prices	
1) 123.05%, 2) 146.10%, 3) 169.15% of the starting value	
Max. amount	169.15% of the nominal value
Capital protec.	100% at the end of term
Quotes	Stuttgart

1 ... Rating: rbinternational.com/ir/ratings

2 ... Early closing or extension of the subscription period is within the sole discretion of Raiffeisen Bank International AG.

How the certificate works

On the initial valuation date, the starting value of the shares are determined and the termination levels are defined. On the respective annual valuation date, the respective closing prices are compared with the respective termination level. If the closing price of the worst performing underlying is at or above the termination level, (early) redemption of the certificate is effected at the predefined termination price:

Annual valuation dates	Is the price of the share greater/equal to ...	Termination price
May 23, 2024	100% of the starting value no ▼	yes ► 123.05%
May 22, 2025	100% of the starting value no ▼	yes ► 146.10%
May 21, 2026	100% of the starting value no ▼	yes ► 169.15%

100 % capital protection at the end of term

In case the closing price of at least one share quotes below the starting value at the end of the term, the capital protection of 100% applies at maturity. In this case, 100% of the nominal value is paid out on the redemption date.

The duration of this product is uncertain as it may terminate at different times depending on how the market evolves. The return is only guaranteed if you hold the product to early call or maturity.


The Certificate is designed for investors who have the following views:

- Investors who believe that the value of all shares may rise in the next three years.
- Investors who are prepared to invest (a portion) of their assets for the entire maturity.
- Investors who do not need to receive regular income from the investment. The Certificate does not pay any dividends.

Novartis AG share

Switzerland-based pharmaceutical company

Novartis develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products.



CH0012005267


As of April 24, 2023; Source: Bloomberg (NOVN SE Equity, ROG SE Equity, SAN FP Equity)

Please note that past performance is no reliable indicator for future results.

Roche Holding AG share

Switzerland-based healthcare company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics.




CH0012032048

Sanofi Aventis S.A. share

French pharmaceutical company

The French Sanofi group is a globally leading pharmaceutical company. The business focuses on the fields of diabetes, cardiovascular diseases, vaccinations and specialty care.



FR0000120578

My market expectation

declining ↘ **sideways →** rising ↗

My investment horizon

< 3 years **3 to 5 years** > 5 years

Note

The referenced opportunities and risks represent a selection of the most important facts regarding the product.

You are about to purchase a product that is not easy and difficult to understand.

For further information, please refer to the base prospectus (including any supplements) approved by the competent authorities - published at raiffeisenzertifikate.at/en/securities-prospectus/ (we recommend reading the prospectus before making an investment decision) - and to the base information sheets as well as to "Customer information and regulatory matters" raiffeisenzertifikate.at/customer-information

Opportunities

- **Yield opportunity:** Opportunity to obtain 23.05% yield if all underlying shares remain at the same level or increase in value.
- **Possible early redemption:** Early redemption at the predefined termination price if all underlying shares quote at or above their respective termination levels at any of the valuation dates.
- **Flexibility:** Tradability on secondary market, no management fees.

Risks

- **Limited yield opportunity:** The maximum yield is limited to 23.05% per annum. If any of the underlying shares does not quote at or above the termination level at any of the three valuation dates, no (early) redemption at the predefined termination price will be effected and investors will not obtain any yield.
- **Capital protection only at the end of the term:** During the term the price of the certificate may drop below the capital protection level. For example, strongly rising interest rates have a negative impact on the price performance of the certificate. The capital protection applies exclusively at the end of the term.
- **Issuer risk / Bail-in:** Certificates are not covered by the Deposit Protection Scheme. Investors are exposed to the risk that Raiffeisen Bank International AG might be unable to fulfill its payment obligations in respect of the described financial instrument such as in the event of insolvency (issuer risk) or an official directive (Bail-in). A total loss of the capital invested is possible.
- **Liquidity risk:** Raiffeisen Bank International AG will attempt to issue daily bid and offer prices for the Certificate under normal market and financing conditions as determined by Raiffeisen Bank International AG at its own discretion. The price depends on the market conditions at the time of trading and may be above or below the issue price. Liquidity may disappear, as a result of which there may be no secondary market for the Certificate. This means that, due to a possible limited market-ability of the Certificate, you must keep the Certificate until Maturity.
- **Other risks:** This brief overview of risks cannot describe all possible risks of the Certificates. Before investing you must fully inform yourself of the risks involved with the Certificate, and consult the Key Information Document (KID) and the Prospectus. These documents can be requested at Raiffeisen Bank International AG and via: www.raiffeisencertificates.com

For further information, please contact your bank advisor, visit [raiffeisenzertifikate.at](https://www.raiffeisenzertifikate.at) or call the Raiffeisen Bank International AG certificate hotline: +43 1/717 07 - 5454 or info@raiffeisenzertifikate.at. Your Raiffeisen Certificates contacts, Am Stadtpark 9, 1030 Vienna/Austria:

Heike Arbter, Head of Division	heike.arbter@rbinternational.com	Gabriele Rihtar	gabriele.rihtar@rbinternational.com
Philipp Arnold, Head of Department	philipp.arnold@rbinternational.com	Daniel Szabo	daniel.szabo@rbinternational.com
Mariusz Adamiak	mariusz.adamiak@rbinternational.com	W. Wagner-Freudenthal	wilhelmine.wagner-freudenthal@rbinternational.com
Raphael Bischinger	raphael.bischinger@rbinternational.com	Roman Bauer, Head of Department	roman.bauer@rbinternational.com
Maida Blentic	maida.blentic@rbinternational.com	Peidong Cao	peidong.cao@rbinternational.com
Anton Bondar	anton.bondar@rbinternational.com	Yung Pin Chen	yungpin.chen@rbinternational.com
Lukas Florreither	lukas.florreither@rbinternational.com	Walter Friehsinger	walter.friehsinger@rbinternational.com
Jan Kausek	jan.kausek@rbinternational.com	Lukas Hackl	lukas.hackl@rbinternational.com
Paul Kieselbach	paul.kieselbach@rbinternational.com	Monika Mrnustikova	monika.mrnustikova@rbinternational.com
Marianne Kögel	marianne.koegel@rbinternational.com	Catarina Penela Amado	catarina.amado@rbinternational.com
Kathrin Korinek	kathrin.korinek@rbinternational.com	Ludwig Schweighofer	ludwig.schweighofer@rbinternational.com
Anna Kujawska	anna.kujawska@rbinternational.com	Martin Vonwald	martin.vonwald@rbinternational.com
Aleksandar Makuljevic	aleksandar.makuljevic@rbinternational.com	Alexander Unger, Head of Department	alexander.unger@rbinternational.com
Patrick Paul	patrick.paul@rbinternational.com	Markus Auer	markus.auer@rbinternational.com
Elisa Pichlbauer	elisa.pichlbauer@rbinternational.com	Levin Gollner	levin.gollner@rbinternational.com
Michal Polin	michael.polin@rbinternational.com	Julius Mozdzierz	julius.mozdzierz@rbinternational.com
Martin Rainer	martin.rainer@rbinternational.com	Veronika Oberpertinger	veronika.oberpertinger@rbinternational.com



DISCLAIMER

In spite of all possible care taken, the data contained in this advertisement are provided purely as non-binding information. This advertisement constitutes neither investment advice nor an offer nor a recommendation nor an invitation to execute a transaction. The information contained in this advertisement is generic and no consideration is given to the personal circumstances of potential investors. The information contained in this advertisement substitutes neither the necessary individual investment advice for the purchase or sale of investments nor shall any investment decision be taken on the basis of this document. This advertisement has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to the prohibition on dealing ahead of the dissemination of investment research.

The complete information for all financial instruments described in this advertisement as well as the sole legal basis for potential transactions in one of the described financial instruments is the Registration Document approved by the Luxembourg Financial Market Authority (CSSF) and the Securities Note approved by the Austrian Financial Market Authority (FMA) - both documents together form the Base Prospectus - together with any supplements and the respective Final Terms of the described financial instrument. The approval of the Base Prospectus should not be construed as an endorsement of the financial instrument described herein by the competent authorities. Additional information on the financial instruments described herein may also be obtained from the respective key information documents (KIDs) that are available for download free of charge on the website of Raiffeisen Bank International AG ([raiffeisenzertifikate.at](https://www.raiffeisenzertifikate.at)) by entering the International Securities Identification Number (ISIN) of the respective financial instrument. Unless otherwise explicitly expressed in any of the cited documents above, no measures have been taken in any national legal system which should permit a public offering of the products described therein. Raiffeisen Bank International AG explicitly excludes any liability in relation to the correctness, appropriateness and completeness of the information presented herein. Certificates are risky instruments of wealth investment. Should the price of the respective underlying instrument of a certificate develop adversely, an investor may lose part or all of his or her invested capital. Certificates react more strongly or weakly to changes of the price of the underlying instrument depending on a number of factors (e.g. volatility or correlation of the underlying instruments, interest, dividends, remaining term, changes in foreign exchange rates) and do not move simultaneously with the underlying. Under certain circumstances the issuer is authorized to redeem the certificates prior to the agreed repayment date.

Issuer Risk/Creditor Participation ("bail-in"): Any payments during or at the end of the term of the certificates depend on the solvency of the issuer ("issuer risk"). Investors are therefore exposed to the risk that Raiffeisen Bank International AG might be unable to fulfil its payment obligations in respect of the described financial instrument such as in the event of insolvency ("issuer risk") or an official directive ("bail-in"). The resolution authority may also issue such an order before any insolvency proceedings if the issuer is judged to be in crisis. Under these circumstances the resolution authority has wide-ranging powers to take action (so-called "bail-in instruments"). For example, it can reduce the claims of investors in respect of the described financial instruments to zero, terminate the described financial instruments, or convert them into shares of the issuer and suspend investors' rights. More detailed further information is available at [raiffeisenzertifikate.at/en/basag](https://www.raiffeisenzertifikate.at/en/basag). A total loss of the invested capital is possible. Past performance is no reliable indicator of future results. Please refer to the Base Prospectus for additional disclosures on risks as well as further information.

The information presented does not constitute binding tax advice. Tax treatment of investments is dependent on the personal situation of the investor and may be subject to change. As regards tax treatment and impact on the investor's individual tax situation, the investor is advised to consult with a tax advisor. This report is based on the knowledge the persons preparing the document have obtained up to the date of creation. Please note that

the legal situation may change due to legislative amendments, tax directives, opinions of financial authorities, jurisdiction etc.

The price of the Express Certificate is dependent on the underlying's price. Adverse performances of the underlying may cause price fluctuations of the Express Certificate. If the Express Certificate is sold, there is the risk to incur a substantial loss or even a total loss of the invested capital ("market risk"). The Express Certificate is subject to several influencing factors and need not develop simultaneously to and in accordance with the underlying's performance. Such influencing factors include e.g. intensity of the underlying's price fluctuations (volatility), interest rates, solvency of the issuer or remaining term. If the Express Certificate is sold prior to the end of the term, there is the risk to incur a partial or even total loss of the invested capital (price performance). Dividends and similar rights associated with the underlying are taken into account when structuring the Express Certificate and are not paid out.

The financial instrument and the associated product documents may not be offered, sold, resold or delivered or published, either directly or indirectly, to natural or legal persons who are resident/registered office in a country in which this is prohibited by law. In no event may this document be distributed in the United States of America ("U.S.A.")/to U.S. persons and the United Kingdom ("UK").

Certificates issued by Raiffeisen Bank International AG are no financial products as defined in the Regulation (EU) 2019/2088.

Supervisory Authorities: Austrian Financial Market Authority (FMA), European Central Bank (ECB). Imprint according to the Austrian Media Act: Media Owner and Publisher is Raiffeisen Bank International AG, Am Stadtpark 9, 1030 Vienna/Austria.